बाजार अवलोकन

The prefilled syringes market was valued at USD 7.2 billion in the base year and is projected to grow at a CAGR of 10.69% over the forecast period.

The global prefilled syringes market experienced a positive impact from the COVID-19 pandemic, as these syringes were widely used for COVID-19 vaccines. The pandemic accelerated the development of prefilled syringes, particularly for vaccines requiring low-temperature storage. For example, in September 2021, Becton, Dickinson, and Company (BD) demonstrated the suitability of their glass prefilled syringes for mRNA COVID-19 vaccines that require ultralow temperature storage. The company highlighted that switching from vials to prefilled syringes can address the cost and complexity of vaccine administration. फलस्वरूप, the outbreak of COVID-19 in 2020 led to increased sales of prefilled syringes globally.

Prefilled syringes have gained popularity as a preferred option for unit-dose medication, as the pharmaceutical industry seeks more convenient drug delivery methods. Self-injectable contraception, for example, has been recognized by the World Health Organization as a self-care intervention that can reduce unintended pregnancies. The organization estimates that individuals spend less than one hour per year with healthcare professionals but over 8700 hours practicing self-care. The increasing adoption of self-care practices is expected to drive the demand for prefilled syringes and fuel market growth.

इसके अतिरिक्त, the increasing prevalence of diseases such as diabetes and rheumatoid arthritis, along with the growing adoption of biosimilars in developed regions, will further propel market expansion. According to a report by SingleCare in January 2022, more than 14.0 million people worldwide suffer from rheumatoid arthritis annually, with over 1.36 million cases in the United States alone. Rheumatoid arthritis is the most common form of autoimmune arthritis in the US, affecting approximately 0.6% को 1.0% of the population each year. As prefilled syringes offer safety at an affordable price, their usage is expected to increase in the future.

इसके अतिरिक्त, the introduction of new products will actively contribute to market growth. In May 2022, Terumo Corporation launched a prefillable polymer syringe for low-dose applications, providing a safe and effective treatment option. Government investments in advanced syringe production will also drive market growth. For example, in March 2022, Hungary invested USD 84.53 million to expand prefillable glass syringe production, aiming to meet the growing global demand. The expansion project is expected to be completed by 2024 and will support the market’s future demand.

However, product recalls and the availability of alternative drug delivery methods are factors that may hinder market growth.

बाजार विभाजन

The market is segmented based on various factors, including material, प्रकार, application, and region.

Segmentation by Material
Glass Prefilled Syringe
Plastic Prefilled Syringe

Segmentation by Type
With Needle
Without Needle

Segmentation by Application
Diabetes
Anaphylaxis
Rheumatoid Arthritis
Oncology
Other Applications

Segmentation by Region
North America – संयुक्त राज्य अमेरिका, कनाडा, and Mexico
Europe – यूनाइटेड किंगडम, जर्मनी, फ्रांस, स्पेन, इटली, and Rest of Europe
Asia-Pacific – चीन, जापान, भारत, South Korea, ऑस्ट्रेलिया, and Rest of Asia-Pacific
Latin America – ब्राज़िल, अर्जेंटीना, and Rest of Latin America
Middle East and Africa – दक्षिण अफ्रीका, GCC, and Rest of Middle East and Africa

In 2022, the glass prefilled syringes segment dominated the market with a share of USD 4,666 दस लाख. It is projected to grow at a CAGR of 9.24% पूर्वानुमान अवधि के दौरान. The increasing demand for glass prefilled syringes can be attributed to their numerous advantages. These syringes are designed to safely deliver drugs or biologics to patients. They can be connected to various devices such as needles, IV lines, adapters, and transfer units. Glass prefilled syringes improve patient safety by reducing the risk of accidental needle sticks and exposure to toxic substances when drawing medication from vials. इसके अतिरिक्त, the premeasured dosages in these syringes help reduce dosing errors and enhance patient compliance.

The with needle segment held the largest share in the market, amounting to USD 3,946 मिलियन इन 2022. It is expected to grow at a CAGR of 10.31% पूर्वानुमान अवधि के दौरान. Prefilled syringes with needles are commonly used for biological and pharmaceutical drug products. Multidose vial needle-prefilled syringes provide basic protection and ease of use, while single-dose prefilled syringes and passive safety devices offer enhanced safety, convenience, and flexibility. The growing use of needle-prefilled syringes is a key factor driving the growth of this segment. इसके अतिरिक्त, the increasing prevalence of diseases such as cancer, cardiovascular disease, ophthalmic disorders, neurological disorders, and autoimmune diseases also contribute to the segment’s growth.

The diabetes segment held the largest share in the market, reaching USD 2,623 मिलियन इन 2022. It is expected to grow at a CAGR of 11.53% पूर्वानुमान अवधि के दौरान. The dominance of the diabetes segment is primarily due to the rising cases of diabetes worldwide. Diabetes is a chronic disease that occurs when the pancreas fails to produce insulin or when the body cannot effectively use the insulin it produces. Prefilled syringes are widely used by diabetes patients for multiple insulin doses. Factors such as a large patient base, increasing prevalence of diabetes, and the need for effective and safe insulin delivery devices contribute to the continued dominance of this segment throughout the forecast period.

The increasing prevalence of diabetes globally is a major driver for market expansion. Diabetes is a significant public health issue that poses threats to public health and socioeconomic development. According to the International Diabetes Federation (IDF), approximately 537 million adults between the ages of 20 और 79 were living with diabetes in 2021. The IDF projects that the number of individuals with diabetes will increase to 63 मिलियन द्वारा 2030 और 783 मिलियन द्वारा 2045.

Major companies like BD are developing prefilled syringes specifically for chronic disease treatment to strengthen their market position. For example, in May 2021, BD announced plans to spin off its Diabetes Care division into a separate publicly-traded company called NewCo. BD Diabetes Care plays a significant role in the adoption of insulin syringes and other products, catering to approximately 30 million patients and producing around 8 billion injection devices annually. Such factors are expected to drive the demand for prefilled syringes in the foreseeable future.

आगे, in March 2022, Novo Nordisk launched its smart insulin pens in the UK, providing people treated within the NHS for diabetes access to devices that can monitor and record dosing information. Similarly, in November 2020, Medtronic PLC introduced InPen integrated with real-time Guardian Connect CGM data. InPen is the first and only FDA-cleared smart insulin pen designed for individuals on multiple daily injections (MDI). These advancements are expected to drive the growth of the corresponding segments in the market during the forecast period.

North America is anticipated to hold a significant market share throughout the forecast period due to healthcare practitioners’ strong preference for prefilled injectable devices, which helps reduce needle-related injuries. इसके अतिरिक्त, the region is home to major market players such as Gerresheimer AG, SCHOTT group, Stevanato Group, Haselmeier AG, and Owen Mumford Ltd. These companies have established a strong presence in the region over the years. फलस्वरूप, the demand for prefilled syringes is increasing in the United States, propelling market growth.

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) update in December 2020, approximately 34.2 million people (10.5% of the population) had diabetes. Patients with Type 1 diabetes often require regular intravenous administration of insulin to manage their blood sugar levels. Prefilled syringes provide convenience and ease of administration for self-administration.

आगे, innovative product launches and approvals in the United States are expected to drive market growth during the forecast period. For instance, in September 2022, BD introduced a new glass pre-fillable syringe called BD Effivax Glass PFS, which aims to set a new performance standard for vaccine PFS. This syringe was developed in collaboration with pharmaceutical companies to meet evolving vaccine manufacturing needs.

इसके अतिरिक्त, in October 2022, West Pharmaceutical Services, इंक. participated in the 2022 Parenteral Drug Association (PDA) Universe of prefilled syringes and Injection Devices Conference, where they presented developments in large volume delivery systems, self-injection devices, and pre-fillable syringe components. These developments are expected to contribute to market growth.

Considering these factors, the North American region is expected to witness promising growth in the studied market over the forecast period.

प्रतिस्पर्धी परिदृश्य

The prefilled syringes market exhibits a fragmented landscape, attributed to the presence of numerous companies. These market participants are diligently implementing various organic and inorganic growth strategies to secure a larger share of revenue within this industry. Notable companies operating in the prefilled syringes market include Becton, Dickinson, and Company, Terumo Corporation, Gerresheimer AG, SCHOTT, West Pharmaceutical Services, Inc., and West Pharmaceutical Services, Inc., among others.

Key Companies Profiled in this report include Becton, Dickinson and Company, Gerresheimer AG, Laboratoire Aguettant, Nipro Corporation, Schott AG, Stevanato Group, Taisei Kako Co., लिमिटेड, Terumo Corporation, West Pharmaceutical Services Inc., Plas-Tech Engineering, इंक.

Recent Industry Developments

In January 2022, Owen Mumford declared the receipt of regulatory approval for its UniSafe 1mL safety device designed for pre-filled syringes in Asia. Similarly, in Europe, UniSafe 1mL has also obtained regulatory approval and is currently accessible in the market as a combination product, alongside a drug used for treating rheumatoid arthritis.

In January 2021, Aurobindo Pharma Limited received authorization from the United States Food and Drug Administration (USFDA) to produce and distribute the Naloxone HCl Injection Prefilled Syringe 2 mg/2 mL.

Key Questions Answered

What is the duration of the research period for this market study?
What is the rate of growth for the Prefilled Syringes Market?
What was the size of the Prefilled Syringes Market in 2018?
What is the projected size of the Prefilled Syringes Market in 2028?
Which region exhibits the highest growth rate in the Prefilled Syringes Market?
Which region holds the largest share in the Prefilled Syringes Market?
Who are the major players in the Prefilled Syringes Market?